Association study of UGT1A9 promoter polymorphisms with Dili based on systematically regional variation screen in Chinese population

Pharmacogenomics Journal

Volumn 15, Issue 4, 2015, Pages 326-331

  Jiang, J ^a,b   Zhang, X ^c   Huo, R ^a,b   Li, X ^a,b   Yang, Y ^d   Gai, Z ^e   Xu, M ^a,b   Shen, L ^a,b   Cai, L ^a,b   Wan, C ^a,b   Li, B ^a,b   He, L ^a,b,f   Qin, S ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai GenomePilot Institutes for Genomics and Human Health   (China)

^c TONGJI UNIVERSITY   (China)

^d NINGXIA MEDICAL UNIVERSITY   (China)

^e SHANDONG UNIVERSITY   (China)

^f FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE; UDP-GLUCURONOSYLTRANSFERASE 1A9;

ADOLESCENT; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CHINA; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL GEOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; REGIONAL VARIATION; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; UGT1A9 GENE; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC POLYMORPHISM; GENETICS; GEOGRAPHY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHINA; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GEOGRAPHY; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 84937815225     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.75     Document Type: Article

References (35)

1. Grant LM, Rockey DC. Drug-induced liver injury. Curr Opin Gastroenterol 2012; 28: 198-202.
2. Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol 2012; 18: 249-257.
3. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 2007; 102: 558-562; quiz 693.
4. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014; 89: 95-106.
5. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16: 3041-3053.
6. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-2404.
7. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J. Druginduced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32: 55-68.
8. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology 2010; 52: 748-761.
9. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005; 45: 177-202.
10. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51: 615-620.
11. Yu ML, Yang Y, Wang CM, Zhang MM, Bai MC, Guo YL. Acitretin exhibits inhibitory effects towards UDP-glucuronosyltransferase (UGT)1A9-mediated 4-methylumbelliferone (4-MU) and propofol glucuronidation reaction. Pharmazie 2013; 68: 449-452.
12. Court MH, Freytsis M, Wang X, Peter I, Guillemette C, Hazarika S, et al. The UDPglucuronosyltransferase (UGT) 1A polymorphism c.2042C4G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther 2013; 345: 297-307.
13. Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, et al. Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. Mol Pharmacol 2005; 67: 241-249.
14. Zakerska O, Skrzypczak-Zielinska M, Mikstacki A, Tamowicz B, Malengowska B, Szalata M, et al. Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population. Eur J Drug Metab Pharmacokinet 2013; 38: 217-221.
15. Xing Y, Yang L, Wang L, Shao L, Wei Z, Xuan J, et al. Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling. Pharmacogenomics 2009; 10: 741-752.
16. Ikushiro S, Emi Y, Iyanagi T. Identification and analysis of drug-responsive expression of UDP-glucuronosyltransferase family 1 (UGT1) isozyme in rat hepatic microsomes using anti-peptide antibodies. Arch Biochem Biophys 1995; 324: 267-272.
17. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14: 501-515.
18. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012; 8: 371-382.
19. Schulz C, Boeck S, Heinemann V, Stemmler HJ. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 2009; 20: 867-879.
20. Tang K, Li X, Xing Q, Li W, Feng G, He L, et al. Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in Chinese Han populations from four different geographic areas of Mainland China. Genomics 2010; 95: 224-229.
21. Wu Z, Zhang X, Shen L, Xiong Y, Wu X, Huo R, et al. A systematically combined genotype and functional combination analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in different geographic areas of mainland China-a basis for personalized therapy. PLoS One 2013; 8: e71934.
22. Qin S, Shen L, Zhang A, Xie J, Shen W, Chen L, et al. Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics 2008; 92: 152-158.
23. Chen L, Qin S, Xie J, Tang J, Yang L, Shen W, et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 2008; 9: 691-702.
24. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19: 376-382.
25. Qin S, Zhao X, Pan Y, Liu J, Feng G, Fu J, et al. An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur J Hum Genet 2005; 13: 807-814.
26. Su MW, Tung KY, Liang PH, Tsai CH, Kuo NW, Lee YL. Gene-gene and ge-eenvironmental interactions of childhood asthma: a multifactor dimension reduction approach. PLoS One 2012; 7: e30694.
27. Yang J, Cai L, Huang H, Liu B, Wu Q. Genetic variations and haplotype diversity of the UGT1 gene cluster in the Chinese population. PLoS One 2012; 7: e33988.
28. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 2011; 7: 875-890.
29. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-243.
30. Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, et al. Association of CYP2C9∗2 with bosentan-induced liver injury. Clin Pharmacol Ther 2013; 94: 678-686.
31. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132: 272-281.
32. Andrade RJ, Agúndez JA, Lucena MI, Martínez C, Cueto R, Garciá-Martín E. Pharmacogenomics in drug induced liver injury. Curr Drug Metab 2009; 10: 956-970.
33. Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM, Selvaggi G, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy 2008; 28: 1188-1193.
34. Martignoni E, Cosentino M, Ferrari M, Porta G, Mattarucchi E, Marino F, et al. Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology 2005; 65: 1820-1822.
35. Liu W, Ramírez J, Gamazon ER, Mirkov S, Chen P, Wu K, et al. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet 2014; 23: 5558-5569.